Cidara Therapeutics Stock Probability of Future Stock Price Finishing Over 39.20

CDTX Stock  USD 23.22  0.71  3.15%   
Cidara Therapeutics' future price is the expected price of Cidara Therapeutics instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Cidara Therapeutics performance during a given time horizon utilizing its historical volatility. Check out Cidara Therapeutics Backtesting, Cidara Therapeutics Valuation, Cidara Therapeutics Correlation, Cidara Therapeutics Hype Analysis, Cidara Therapeutics Volatility, Cidara Therapeutics History as well as Cidara Therapeutics Performance.
For more information on how to buy Cidara Stock please use our How to Invest in Cidara Therapeutics guide.
  
Price To Sales Ratio is likely to drop to 1.03 in 2024. Price Earnings Ratio is likely to drop to -3.18 in 2024. Please specify Cidara Therapeutics' target price for which you would like Cidara Therapeutics odds to be computed.

Cidara Therapeutics Target Price Odds to finish over 39.20

The tendency of Cidara Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move over $ 39.20  or more in 90 days
 23.22 90 days 39.20 
near 1
Based on a normal probability distribution, the odds of Cidara Therapeutics to move over $ 39.20  or more in 90 days from now is near 1 (This Cidara Therapeutics probability density function shows the probability of Cidara Stock to fall within a particular range of prices over 90 days) . Probability of Cidara Therapeutics price to stay between its current price of $ 23.22  and $ 39.20  at the end of the 90-day period is under 4.
Given the investment horizon of 90 days the stock has the beta coefficient of 1.37 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Cidara Therapeutics will likely underperform. Moreover Cidara Therapeutics has an alpha of 1.1361, implying that it can generate a 1.14 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   Cidara Therapeutics Price Density   
       Price  

Predictive Modules for Cidara Therapeutics

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Cidara Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Cidara Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
18.7624.1529.54
Details
Intrinsic
Valuation
LowRealHigh
6.3511.7425.54
Details
Naive
Forecast
LowNextHigh
16.1021.4926.87
Details
4 Analysts
Consensus
LowTargetHigh
5.105.606.22
Details

Cidara Therapeutics Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Cidara Therapeutics is not an exception. The market had few large corrections towards the Cidara Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Cidara Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Cidara Therapeutics within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
1.14
β
Beta against Dow Jones1.37
σ
Overall volatility
4.49
Ir
Information ratio 0.21

Cidara Therapeutics Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Cidara Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Cidara Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Cidara Therapeutics is way too risky over 90 days horizon
Cidara Therapeutics appears to be risky and price may revert if volatility continues
The company reported the previous year's revenue of 63.91 M. Net Loss for the year was (22.93 M) with loss before overhead, payroll, taxes, and interest of (11.23 M).
Cidara Therapeutics currently holds about 53.08 M in cash with (22.43 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.74.
Cidara Therapeutics has a frail financial position based on the latest SEC disclosures
Latest headline from news.google.com: Cidara Therapeutics Just Flashed Golden Cross Signal Do You Buy - MSN

Cidara Therapeutics Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Cidara Stock often depends not only on the future outlook of the current and potential Cidara Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Cidara Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding4.4 M
Cash And Short Term Investments35.8 M

Cidara Therapeutics Technical Analysis

Cidara Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Cidara Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Cidara Therapeutics. In general, you should focus on analyzing Cidara Stock price patterns and their correlations with different microeconomic environments and drivers.

Cidara Therapeutics Predictive Forecast Models

Cidara Therapeutics' time-series forecasting models is one of many Cidara Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Cidara Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

Things to note about Cidara Therapeutics

Checking the ongoing alerts about Cidara Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Cidara Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Cidara Therapeutics is way too risky over 90 days horizon
Cidara Therapeutics appears to be risky and price may revert if volatility continues
The company reported the previous year's revenue of 63.91 M. Net Loss for the year was (22.93 M) with loss before overhead, payroll, taxes, and interest of (11.23 M).
Cidara Therapeutics currently holds about 53.08 M in cash with (22.43 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.74.
Cidara Therapeutics has a frail financial position based on the latest SEC disclosures
Latest headline from news.google.com: Cidara Therapeutics Just Flashed Golden Cross Signal Do You Buy - MSN

Additional Tools for Cidara Stock Analysis

When running Cidara Therapeutics' price analysis, check to measure Cidara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cidara Therapeutics is operating at the current time. Most of Cidara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cidara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cidara Therapeutics' price. Additionally, you may evaluate how the addition of Cidara Therapeutics to your portfolios can decrease your overall portfolio volatility.